The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase ...

To advance the understanding and treatment of liver disease by pursuing innovative, transformative basic and translational ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today ...

FibroNest digital pathology in liver biopsies from patients with MASH FibroNest digital pathology augmented image for ...

A new study published in the New England Journal Of Medicine claimed that it can tackle non-alcoholic steatohepatitis or NASH ...

Despite growing policy uncertainty, plenty of healthcare companies have managed to put up big returns, thanks to these ...

Dawn Health and Merck have launched the next-generation digital ecosystem for growth disorders, designed to support patients with Growth Hormone Deficiency (GHD), their caregivers, and healthcare ...

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor ...